Clinical outcomes after therapy with forodesine
. | . | BM disease, % . | . | WBC count, × 109/L . | . | Absolute PB leukemia, × 109/L . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | No. of courses . | Before . | After . | Before . | After . | Before . | After . | Other observations . | Overall response, course 1 . | |||
| 1 | 1 | 94 | 12 | 4.4 | 6.1 | Detectable only by flow cytometry | Detectable only by flow cytometry | 25% decrease in adenopathy, pleural effusion | SD | |||
| 2 | 2 | 55 | 69 | 21.3 | 45.8 | 92.2 | 20.2 | — | SD | |||
| 3 | 1 | 90 | ND | 87.1 | 200.5* | 44.4 | 26.6* | No change LN/spleen | PD | |||
| 4 | 1 | 78 | 97† | 14.8 | 0.7 | 10.9 | 0.14 | — | PD | |||
| 5 | 4 | 91 | 19 | 150.6 | 17.2 | 102.4 | 3.96 | No change LN/spleen | SD | |||
. | . | BM disease, % . | . | WBC count, × 109/L . | . | Absolute PB leukemia, × 109/L . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | No. of courses . | Before . | After . | Before . | After . | Before . | After . | Other observations . | Overall response, course 1 . | |||
| 1 | 1 | 94 | 12 | 4.4 | 6.1 | Detectable only by flow cytometry | Detectable only by flow cytometry | 25% decrease in adenopathy, pleural effusion | SD | |||
| 2 | 2 | 55 | 69 | 21.3 | 45.8 | 92.2 | 20.2 | — | SD | |||
| 3 | 1 | 90 | ND | 87.1 | 200.5* | 44.4 | 26.6* | No change LN/spleen | PD | |||
| 4 | 1 | 78 | 97† | 14.8 | 0.7 | 10.9 | 0.14 | — | PD | |||
| 5 | 4 | 91 | 19 | 150.6 | 17.2 | 102.4 | 3.96 | No change LN/spleen | SD | |||
No improvement in transfusion requirements were observed (all patients were transfusion-dependent prior to forodesine treatment). Details are provided for course 1 only, with posttherapy assessments at day 21 unless otherwise indicated. Refer to text and Figure 2A-C for additional details.
SD indicates stable disease; PD, progressive disease; ND, not done.
Day 10
Day 14 bone marrow aspiration showed 3% blasts without morphologically detectable LL cells